Genmab A/S and AbbVie: Genmab and AbbVie Provide Clarification on Phase 3 EPCORE DLBCL-1 Trial Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymph
Genmab (GMAB) and AbbVie (ABBV) clarified that in the U.S. portion of the Phase 3 EPCORE DLBCL-1 trial of epcoritamab (Epcoritamab) for relapsed/refractory DLBCL, overall survival (OS) was the sole primary endpoint and was not met. The trial compares epcoritamab vs investigator’s choice chemotherapy. Results will be submitted for publication.
How this was made
The 30-second read
Why it matters
The key new clarification is that, in the U.S., overall survival was the sole primary endpoint and it was not met, confirming a statistically significant OS improvement was not achieved.
Market read
Endpoint clarification for a Phase 3 program can shift expectations for epcoritamab’s next regulatory and development steps in DLBCL, especially for transplant-ineligible patients.
What to watch
The release frames OS as the sole U.S. primary endpoint and notes additional results will be submitted for publication; details in the full dataset could change the interpretation beyond the headline endpoint.
Background
Genmab and AbbVie previously announced EPCORE DLBCL-1 topline results (Jan 16, 2026) and later presented additional results at EHA 2026 (Jun 12, 2026).
Ticker impact
Genmab clarifies that in the U.S. EPCORE DLBCL-1 trial, overall survival was the sole primary endpoint and was not met.
Near-term sentiment likely negative for GMAB, with focus shifting to other EPCORE programs (DLBCL-2 and DLBCL-4) and ongoing publication.
The article discloses a key endpoint clarification tied to the U.S. primary endpoint and confirms lack of statistical improvement in OS, which typically pressures valuation for the specific indication and trial program.
AbbVie confirms the U.S. EPCORE DLBCL-1 trial did not demonstrate statistically significant overall survival improvement versus chemoimmunotherapy.
Likely modest-to-negative reaction for ABBV, with investors rebalancing toward other epcoritamab studies and commercialization plans.
The companies provide a concrete trial-level outcome statement (OS sole U.S. primary endpoint, not met), which is directly relevant to the co-developed asset’s clinical trajectory.
Market effects
Adds incremental evidence on the difficulty of improving OS in relapsed/refractory DLBCL with T-cell engaging bispecifics versus chemoimmunotherapy in transplant-ineligible patients.
Primarily U.S. trial endpoint clarification, but may influence global investor sentiment toward bispecific lymphoma programs.
Supports a broader reassessment of bispecific efficacy expectations in DLBCL OS endpoints across regions.
Counterpoint
Investors may discount EPCORE DLBCL-1’s U.S. OS miss if other endpoints or subgroups remain favorable, and if upcoming EPCORE DLBCL-2 and DLBCL-4 data show better risk-benefit.
Key entities
- clinical_trialEPCORE DLBCL-1
Phase 3 randomized trial of epcoritamab monotherapy versus investigator’s choice chemoimmunotherapy in relapsed/refractory DLBCL patients ineligible for autologous stem cell transplant.
- drugepcoritamab (DuoBody-CD3xCD20)
T-cell engaging bispecific antibody co-developed by Genmab and AbbVie; approved in certain lymphoma indications under brand EPKINLY/TEPKINLY.
- companyGenmab
Co-developer of epcoritamab and sponsor/clarifier of EPCORE DLBCL-1 endpoint details.
- companyAbbVie
Co-developer of epcoritamab and commercialization partner; provides clarification on EPCORE DLBCL-1 U.S. primary endpoint outcome.
